Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism)

BackgroundThromboembolic disease is a major cause of mortality and morbidity Current anticoagulant therapies have several caveats in the clinical use. New oral antithrombin (Dabigatran) provides comparable or superior thromboprophylaxis in multiple thromboembolic disease indications compared to standard of care.Aim of this workTo evaluate the role of a new oral antithrombin, in management of thrombophilia presented with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction).Patient and methodsThis work was done on 100 patients with thrombophilia associated with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction). They were divided into 2 groups Group I: treated by LMW heparin. Group II: treated by dabigatran. The following was done for all patients. Thorough history taking, complete physical examination, investigations including CT, D Dimer, INR, APTT, Platelet count, Chest X ray P/A and lateral view, CT chest and/or Brain, ECG, CKMB and troponin when needed.ResultsThe percentage of Stroke/TIA, AF/MI, PE, mixed and peripheral thrombotic events were 30, 24, 23, 26 and 6 patients respectively.